186 related articles for article (PubMed ID: 34052626)
1. Targeting CD276 by CAR-T cells induces regression of esophagus squamous cell carcinoma in xenograft mouse models.
Xuan Y; Sheng Y; Zhang D; Zhang K; Zhang Z; Ping Y; Wang S; Shi X; Lian J; Liu K; Zhang Y; Li F
Transl Oncol; 2021 Aug; 14(8):101138. PubMed ID: 34052626
[TBL] [Abstract][Full Text] [Related]
2. CD276 suppresses CAR-T cell function by promoting tumor cell glycolysis in esophageal squamous cell carcinoma.
Yue G; Tang J; Zhang L; Niu H; Li H; Luo S
J Gastrointest Oncol; 2021 Feb; 12(1):38-51. PubMed ID: 33708423
[TBL] [Abstract][Full Text] [Related]
3. CD276-CAR T cells and Dual-CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models.
Timpanaro A; Piccand C; Dzhumashev D; Anton-Joseph S; Robbi A; Moser J; Rössler J; Bernasconi M
J Exp Clin Cancer Res; 2023 Nov; 42(1):293. PubMed ID: 37924157
[TBL] [Abstract][Full Text] [Related]
4. EphA2 chimeric antigen receptor-modified T cells for the immunotherapy of esophageal squamous cell carcinoma.
Shi H; Yu F; Mao Y; Ju Q; Wu Y; Bai W; Wang P; Xu R; Jiang M; Shi J
J Thorac Dis; 2018 May; 10(5):2779-2788. PubMed ID: 29997940
[TBL] [Abstract][Full Text] [Related]
5. Antitumor responses in gastric cancer by targeting B7H3 via chimeric antigen receptor T cells.
Sun F; Yu X; Ju R; Wang Z; Wang Y
Cancer Cell Int; 2022 Jan; 22(1):50. PubMed ID: 35101032
[TBL] [Abstract][Full Text] [Related]
6. CD276 promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma through the TGF-β/SMAD signaling.
Zhang X; Xu C; Wang C; Pei Y; He M; Wan Z; Hou J; Wang L
Clin Exp Metastasis; 2024 Apr; 41(2):81-90. PubMed ID: 38396262
[TBL] [Abstract][Full Text] [Related]
7. Role of Epidermal Growth Factor Receptor-Specific CAR-T Cells in the Suppression of Esophageal Squamous Cell Carcinoma.
Cheng C; Cui H; Liu H; Wu Y; Ding N; Weng Y; Zhang W; Cui Y
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551506
[TBL] [Abstract][Full Text] [Related]
8. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
[TBL] [Abstract][Full Text] [Related]
9. CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing.
Andersch L; Radke J; Klaus A; Schwiebert S; Winkler A; Schumann E; Grunewald L; Zirngibl F; Flemmig C; Jensen MC; Rossig C; Joussen A; Henssen A; Eggert A; Schulte JH; Künkele A
BMC Cancer; 2019 Sep; 19(1):895. PubMed ID: 31500597
[TBL] [Abstract][Full Text] [Related]
10. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
[TBL] [Abstract][Full Text] [Related]
11. CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm.
Bôle-Richard E; Fredon M; Biichlé S; Anna F; Certoux JM; Renosi F; Tsé F; Molimard C; Valmary-Degano S; Jenvrin A; Warda W; Pallandre JR; Bonnefoy F; Poussard M; Deschamps M; Petrella T; Roumier C; Macintyre E; Féger F; Brissot E; Mohty M; HoWangYin KY; Langlade-Demoyen P; Loustau M; Caumartin J; Godet Y; Binda D; Pagadoy M; Deconinck E; Daguindau E; Saas P; Ferrand C; Angelot-Delettre F; Adotévi O; Garnache-Ottou F
Leukemia; 2020 Dec; 34(12):3228-3241. PubMed ID: 32111969
[TBL] [Abstract][Full Text] [Related]
12. Suppressor of cytokine signaling-1 gene therapy induces potent antitumor effect in patient-derived esophageal squamous cell carcinoma xenograft mice.
Sugase T; Takahashi T; Serada S; Nakatsuka R; Fujimoto M; Ohkawara T; Hara H; Nishigaki T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Kishimoto T; Mori M; Doki Y; Naka T
Int J Cancer; 2017 Jun; 140(11):2608-2621. PubMed ID: 28233302
[TBL] [Abstract][Full Text] [Related]
13. Effective Targeting of TAG72
Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
Front Immunol; 2018; 9():2268. PubMed ID: 30510550
[TBL] [Abstract][Full Text] [Related]
14. Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients.
Yu J; Wu X; Yan J; Yu H; Xu L; Chi Z; Sheng X; Si L; Cui C; Dai J; Ma M; Xu T; Kong Y; Guo J
J Hematol Oncol; 2018 Jan; 11(1):1. PubMed ID: 29298689
[TBL] [Abstract][Full Text] [Related]
15. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
16. CD28 Co-Stimulus Achieves Superior CAR T Cell Effector Function against Solid Tumors Than 4-1BB Co-Stimulus.
Textor A; Grunewald L; Anders K; Klaus A; Schwiebert S; Winkler A; Stecklum M; Rolff J; Henssen AG; Höpken UE; Eggert A; Schulte JH; Jensen MC; Blankenstein T; Künkele A
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33801448
[TBL] [Abstract][Full Text] [Related]
17. Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma.
Harada E; Serada S; Fujimoto M; Takahashi Y; Takahashi T; Hara H; Nakatsuka R; Sugase T; Nishigaki T; Saito Y; Hiramatsu K; Nojima S; Mitsuo R; Ohkawara T; Morii E; Mori M; Doki Y; Kaneda Y; Naka T
Oncotarget; 2017 Apr; 8(15):24741-24752. PubMed ID: 28445969
[TBL] [Abstract][Full Text] [Related]
18. Tenascin-C, a Prognostic Determinant of Esophageal Squamous Cell Carcinoma.
Yang ZT; Yeo SY; Yin YX; Lin ZH; Lee HM; Xuan YH; Cui Y; Kim SH
PLoS One; 2016; 11(1):e0145807. PubMed ID: 26731558
[TBL] [Abstract][Full Text] [Related]
19. Targeting GPC2 on intraocular and CNS metastatic retinoblastomas with local and systemic delivery of CAR T-cells.
Pascual-Pasto G; McIntyre B; Giudice AM; Alikarami F; Morrissey A; Matlaga S; Hofmann TJ; Burgueño V; Harvey K; Martinez D; Shah AC; Foster JB; Pogoriler J; Eagle RC; Carcaboso AM; Shields CL; Leahey AM; Bosse KR
Clin Cancer Res; 2024 Jun; ():. PubMed ID: 38864848
[TBL] [Abstract][Full Text] [Related]
20. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
[No Abstract] [Full Text] [Related]
[Next] [New Search]
